COMMUNIQUÉS West-GlobeNewswire

Deinove : le processus d'industrialisation du programme caroténoïdes entre en phase II

05/07/2017 - 18:00

DEINOVE : LE PROCESSUS D'INDUSTRIALISATION DU PROGRAMME CAROTÉNOÏDES ENTRE EN PHASE II La Phase I du programme a permis de sélectionner la première molécule caroténoïde qui sera produite à échelle industrielle courant [...]

Deinove: the industrialization process of the carotenoids program enters phase II

05/07/2017 - 18:00

DEINOVE: THE INDUSTRIALIZATION PROCESS OF THE CAROTENOIDS PROGRAM ENTERS PHASE II Phase I of the program selected the first carotenoid molecule to be produced on an industrial scale in 2018. The yields obtained in 20- [...]

Solon Eiendom ASA - Primary insider notification

05/07/2017 - 17:39

SOLON EIENDOM ASA STOCK EXCHANGE ANNOUNCEMENT Solon Eiendom ASA - Primary insider notification (Oslo, Norway, 5 July 2017) Solon Eiendom ASA Board Member Tore Aksel Voldberg (through his wholly owned company Skøien AS) [...]

ProMIS Neurosciences to Present Preclinical Data from Alzheimer's Disease Program at AAIC 2017

05/07/2017 - 15:01

Chief Development Officer Dr. Johanne Kaplan to chair session ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC): 16-20 JULY, 2017 LONDON, ENGLAND TORONTO, Ontario and CAMBRIDGE, Massachusetts - July 5, 2017 - [...]

Medibio Appoints Mental Healthcare Advocate and Former Congressman, Patrick Kennedy, to Board of Directors

05/07/2017 - 15:00

SYDNEY, Australia and MINNEAPOLIS, July 05, 2017 (GLOBE NEWSWIRE) -- Australian Stock Exchange listed medical technology company Medibio Limited (MEB or the Company) is pleased to announce the appointment of The [...]

Auris Medical Completes Enrollment of Phase 3 HEALOS Trial of AM-111 for the Treatment of Sudden Deafness

05/07/2017 - 14:00

Top-line results from the HEALOS trial are expected in the fall of 2017 Zug, Switzerland, July 5, 2017 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that [...]

ProQR's Drug Candidate QRX-411 for Usher Syndrome Receives Orphan Drug Designation from FDA and EMA

05/07/2017 - 13:00

Key Updates ProQR's QRX-411 receives Orphan Drug Designation by the FDA and EMA for the treatment of retinitis pigmentosa, including Usher syndrome, the subtype targeted by QRX-411. Usher syndrome is an inherited [...]

Publishing of Orion Corporation's Half-Yearly Report for January-June 2017 on 19 July 2017

05/07/2017 - 11:15

ORION CORPORATION PRESS RELEASE 5 JULY 2017 at 12.15 EEST Publishing of Orion Corporation's Half-Yearly Report for January-June 2017 on 19 July 2017 Orion will publish its Half-Yearly Report for January-June 2017 on [...]

MPI raised SEK 10,3 million in rights issue

05/07/2017 - 11:01

Hoersholm, Denmark, July 5 th, 2017 - Medical Prognosis Institute A/S ("MPI") today announced that approximately SEK 10,3 million before issue costs has been raised. This amount secures financing until H2 2018. A total [...]

Acarix Receives First German Commercial Order For CADScor®System For Early Detection Of Coronary Artery Disease From Private Cardiology Clinic In Berlin

05/07/2017 - 08:00

Malmö, July 5, 2017 Acarix Receives First German Commercial Order For CADScor ® System For Early Detection Of Coronary Artery Disease From Private Cardiology Clinic In Berlin Commercialization program on track as [...]

IBA SA : IBA signe un contrat pour l'installation d'un centre de protonthérapie en Virginie, États-Unis

05/07/2017 - 07:35

IBA signe un contrat pour l'installation d'un centre de protonthérapie en Virginie, États-Unis Contrat signé avec Inova Health Care Services pour l'installation d'une solution Proteus ® PLUS avec deux salles de [...]

IBA SA : IBA to Install Proton Therapy Center in Virginia, USA

05/07/2017 - 07:35

IBA to Install Proton Therapy Center in Virginia, USA Contract signed with Inova Health Care Services for two-room Proteus ® PLUS* proton therapy system near IBA's North American Headquarters Reston, VA, USA, July 5 th [...]

New Phase 2 study with filgotinib in non-infectious uveitis

05/07/2017 - 07:30

Mechelen, Belgium; 5 July 2017; 7.30 CET - Galapagos NV (Euronext & NASDAQ: GLPG) announces a new Phase 2 study investigating filgotinib in non-infectious uveitis, being led by filgotinib collaboration partner [...]

ESPERITE (ESP): L1 Capital subscribes to the fourth packed tranche of investment today

05/07/2017 - 07:17

Zutphen, The Netherlands, 5 July 2017 Esperite N.V. (Euronext: ESP, "Esperite" or "the Group") announces that today a fourth Packed Tranche of EUR 250,000 is issued as a private placement of 25 convertible notes (the " [...]

NEOVACS ANNOUNCES LICENSE AGREEMENT FOR IFNalpha KINOID FOR TREATMENT OF LUPUS IN TURKEY

05/07/2017 - 07:00

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS ANNOUNCES LICENSE AGREEMENT FOR IFNalpha KINOID FOR TREATMENT OF LUPUS IN TURKEY Agreement grants Centurion Pharma exclusive license to market IFNalpha Kinoid in [...]

NEOVACS ANNONCE LA SIGNATURE D'UN ACCORD DE LICENCE POUR L'IFNalpha KINOIDE DANS LE TRAITEMENT DU LUPUS EN TURQUIE

05/07/2017 - 07:00

COMMUNIQUE DE PRESSE · COMMUNIQUE DE PRESSE · COMMUNIQUE DE PRESSE NEOVACS ANNONCE LA SIGNATURE D'UN ACCORD DE LICENCE POUR L'IFNalpha KINOIDE DANS LE TRAITEMENT DU LUPUS EN TURQUIE Dans le cadre de cet accord, [...]

IBA SA : IBA Déclaration Intermédiaire

05/07/2017 - 07:00

IBA Déclaration Intermédiaire Une conférence téléphonique au sujet de cette déclaration intermédiaire se tiendra ce jour à 15h CEST, 14h BST, 9h EST. Louvain-La-Neuve, Belgique, le 5 juillet 2017 - IBA (Ion Beam [...]

IBA SA : IBA Trading Update

05/07/2017 - 07:00

IBA Trading Update A conference call to discuss the trading update will be held today at 3pm CEST, 2pm BST, 9am EDT, details below. Louvain-La-Neuve, Belgium, July 5, 2017 - IBA (Ion Beam Applications S.A., EURONEXT), [...]

Saniona AB: Saniona buys out payment obligation to NeuroSearch

04/07/2017 - 18:00

PRESS RELEASE 4 July 2017 Saniona, a leading biotech company in the field of ion channels, today announce that it has acquired NeuroSearch's remaining interest in the preclinical and clinical assets, which Saniona [...]